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OBJECTIVES:   
To study the histopathological features of various subtypes of Hepatoblastoma and to 
correlate the immunohistochemical expression of CK19, Beta-catenin & EpCAM, with 
histological parameters of tumour behaviour and survival.  
METHODS:  
Fifty five cases of HB were included in this study. Detailed histopathological examination of 
was done. Immunohistochemical expression of CK19, Beta-catenin and EpCAM were 
correlated with histological subtypes, tumour behaviour, response to chemotherapy and 
survival. Chi-square/ Fisher’s exact test was used to compare the association between 
categorical variables. ‘p’ value of less than 0.05 was considered significant. The overall 
survival (OS) and event free survival (EFS) were calculated. Kaplan-Meier curve was used to 
depict the survival and log rank test was used to compare the survival in different groups. 
 
 
RESULTS:  
Most common epithelial subtype was fetal (43.18%) and mixed epithelial (54.83 %) in pre 
and post-chemotherapy groups respectively. CK19 was expressed in 54.17% and 72.22% of 
embryonal component, nuclear beta-catenin in 48.65% and 57.14% and EpCAM in 100% and 
82.14% of tumours in pre and post-chemotherapy groups respectively. Fetal subtype had a 
better outcome. Nuclear beta-catenin expression was associated with lower EFS and strong 
EpCAM expression with tumour viability. Age ≤2yrs, male sex, alpha-feto protein<10000 
IU/ml post-chemotherapy, multifocality, size ≤5cm, PRETEXT I&II, mitosis ≤2/10hpf, 
microvascular invasion and viable tumour <50%predicted higher EFS. 
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